Weekly digest: the latest news on topics important to Open Pharma

Featuring the importance of net neutrality freedoms for science, the Open Pharma workstream June report and a defence of post-publication peer review.

What do threats to net neutrality mean for scholarly publishing? via PLOS Blogs

In the wake of the widespread  protests in support of net neutrality that took place on Wednesday, this blog reflects on what the US Federal Communication Commission’s proposed changes could mean for scholarly publishing, both in the USA and worldwide.

An interview with PeerJ editor Kenneth De Baets via PeerJ blog

This interview with the editor of innovative journal PeerJ explores a variety of topics related to scholarly publishing, including the paradox of low costs and high fees in digital publishing.

Open Pharma workstream June report via Open Pharma blog

A summary of the latest meetings on the four workstreams: open access; ORCID, CRediT and Convey; preprints and post-publication peer review; and layered publication models.

Resources for creating open publishing policies and initiatives via Open Research Funders Group

This page offers explainers, research and case studies on the implementation of open publishing initiatives for funders to use when developing their own positions.

The Publishers Association raises concerns over Scholarly Communications Licence proposals via The Publishers Association

Following proposals by a scholarly communications working group to introduce a new licence type for higher education institutions, the Publishers Association has shared its concerns about the proposals.

The pros and cons of open access via The Guardian

A range of responses to Stephen Buranyi’s ‘long read’ article on the profitability of scientific publishing.

Biologists debate the use of preprints via Wired

This article is full of useful and interesting information about the place of preprints in the evolving landscape of biological research.

Open peer review study flops via Open Pharma blog

A response by Open Pharma Chair Richard Smith to the study on open peer review recently published in PLoS One.

Leave a Reply